The influence of acute kidney injury (AKI) and renal recovery in deceased donor (DD) on long-term kidney transplant (KT) outcome has not previously been elucidated in large registry study. Our retrospective cohort study included all DDKT performed in Thailand between 2001 and 2018. Donor data was reviewed case by case. AKI was diagnosed according to the KDIGO criteria. Renal recovery was defined if DD had an improvement in AKI to the normal or lower stage. All outcomes were determined until the end of 2020. This study enrolled 4234 KT recipients from 2198 DD. The KDIGO staging of AKI was as follows: stage 1 for 710 donors (32.3%), stage 2 for 490 donors (22.3%) and stage 3 for 342 donors (15.6%). AKI was partial and complete recovery in 265 (17.2%) and 287 (18.6%) before procurement, respectively. Persistent AKI was revealed in 1906 KT of 990 (45%) DD. The ongoing AKI in DD significantly increases the risk of DGF development in the adjusted model (HR 1.69; 95% CI 1.44–1.99; p < 0.001). KT from DD with AKI and partial/complete recovery was associated with a lower risk of transplant loss (log-rank P = 0.04) and recipient mortality (log-rank P = 0.042) than ongoing AKI. KT from a donor with ongoing stage 3 AKI was associated with a higher risk of all-cause graft loss (HR 1.8; 95% CI 1.12–2.88; p = 0.02) and mortality (HR 2.19; 95% CI 1.09–4.41; p = 0.03) than stage 3 AKI with renal recovery. Persistent AKI, but not recovered AKI, significantly increases the risk of DGF. Utilizing kidneys from donors with improving AKI is generally safe. KT from donors with persistent AKI stage 3 results in a higher risk of transplant failure and recipient mortality. Therefore, meticulous pretransplant evaluation of such kidneys and intensive surveillance after KT is recommended.
The lower humoral immunity response after the COVID-19 vaccine in kidney transplant recipients (KTR) has been reported in several studies. However, there are few studies on the efficacy of the ChAdOx1 nCoV-19 (AstraZeneca) vaccine compared between various immunosuppressive regimens. We conducted a prospective cohort study at Siriraj Hospital, Bangkok, Thailand. Adult KTRs who received two doses of the ChAdOx1 nCoV-19 vaccine at intervals of 3 months were enrolled. Anti-SARS-COV-2 S-RBD-IgG antibody (anti-RBD) was assessed at the one month after the second dose and considered positive if the level ≥50 AU/mL or 7 BAU/mL. The primary outcome was the seropositivity of anti-RBD. The association between type, dose, and level of immunosuppressive regimen and anti-RBD seropositivity was analyzed. Between October 2021 and January 2022, 139 KTRs with a median time of 55 months (IQR, 29-102 months), were enrolled. The mean age was 49.1 ± 11.3 years and 64.7 % were men. Seroconversion of anti-RBD was found in 72 patients (51.8 %). The seropositive rate was significantly higher in KTR who received tacrolimus (TAC)/everolimus (EVR)/prednisolone (CS) immunosuppression than EVR/mycophenolic acid (MPA)/CS and TAC/MPA/CS, respectively (95 % vs. 65 % vs. 34 %; p < 0.001). The MPA-containing regimen is associated with an inferior humoral response (OR 0.02, 95%CI 0.01-0.16; p < 0.001). In contrast, KTRs who received EVR had the highest immunogenic response (OR 12.97, 95%CI 4.69-35.84; p < 0.001). During the 11-month follow-up period, COVID-19 pneumonia occurred in 3 KTR in the seronegative group and none in the seropositive group. The anti-RBD response after ChAdOx1 nCoV-19 vaccination was revealed in 51.8 % of the KTR. KTRs who received the TAC/EVR/CS regimen had the highest immune response after vaccination, relatively comparable to the general population. The immunosuppressive regimen should be considered for a further vaccine dose in KTR.
Background: Differentiating glomerular from non-glomerular hematuria remains challenging. Automated urine analyzers with red blood cell (RBC) discrimination algorithms may provide an adjunct to conventional urine microscopy. We evaluated the diagnostic performance of the UF-5000 analyzer for detecting glomerular hematuria (GH). Methods: In this cross-sectional diagnostic study, patients with hematuria were classified into a GH group with biopsy-proven glomerular disease and a non-glomerular hematuria (NGH) group with non-glomerular causes confirmed by clinical, radiological, and/or pathological evaluation. Urine specimens were analyzed by a technician, a nephrology fellow, and the UF-5000 analyzer. Diagnostic performance was assessed using receiver operating characteristic (ROC) curve analysis and multivariable logistic regression. Results: A total of 201 patients were included, comprising 101 in the GH group and 100 in the NGH group. Urinary RBC distribution (URD) from UF-5000 analyzer was significantly higher in the GH group (66.3 ± 23.6 vs. 12.6 ± 19.8%; p < 0.0001). URD demonstrated the highest diagnostic performance among evaluated UF-5000 parameters, with an area under the ROC curve (AUC) of 0.946 (95% CI 0.914–0.979). The optimal Youden-derived URD cutoff ≥ 25% yielded 91.1% sensitivity and 89.0% specificity for identifying GH. Compared with microscopy, URD showed higher sensitivity than technician-performed microscopy (91.1% vs. 60.4%; p < 0.001) and similar performance to fellow-performed microscopy (91.1% vs. 83.2%; p = 0.237). Performance remained consistent across RBC count strata and major glomerular disease subtypes. Conclusions: URD was strongly associated with GH and demonstrated good discriminatory performance in this biopsy-based cohort. Automated urinary RBC analysis may complement conventional urine microscopy in hematuria evaluation.
Prolonged cold ischemia time (CIT) is associated with delayed graft function (DGF), but its impact on long-term outcomes remains uncertain in Asian decease
The Thai Transplantation Society developed these clinical practice guidelines to establish a comprehensive standard for immunosuppressive therapy in adult kidney transplantation. While rooted in evidence‐based medicine, the objective of this document extends beyond local application, serving as a practical model for low‐to‐middle‐income countries, particularly within the Asia‐Pacific and Southeast Asian regions, where specific genetic profiles and resource limitations require tailored management strategies. This publication addresses a critical need in the field, as there has been no updated comprehensive international consensus on immunosuppression since the KDIGO Clinical Practice Guideline in 2009, over 17 years ago. These guidelines bridge this gap by synthesizing modern clinical data with practical applicability. The scope of the guidelines is extensive, covering all aspects of immunosuppression usage including induction, maintenance, therapeutic drug monitoring, and the treatment of rejection. Uniquely, this document addresses specific challenges relevant to resource‐limited settings, offering protocols for cost reduction through the use of generic drugs and the co‐administration of cytochrome P450 3A4 and 3A5 inhibitors to minimize dosage requirements. Furthermore, it provides distinct guidance for immunosuppression in special clinical settings, including management during periods of fasting, pregnancy, and malignancy. This guideline ultimately benefits clinicians by offering a pragmatic, updated reference that balances therapeutic efficacy with economic sustainability.